Board of Pharmacy protocol, naloxone is available by patient request or pharmacist suggestion. A furnishing pharmacist is required to screen and educate patients on opioid overdose prevention, recognition, and response. With patient consent, the pharmacist must notify the primary physician that naloxone was furnished. We estimated the availability of pharmacist-furnished naloxone 2 years after implementation.
Methods | The Office for Human Research Protections at
Claremont Graduate University deemed this study nonhuman research. An anonymous telephone survey of a 20% random sample of California community pharmacies was conducted between January 23 and February 28, 2018. The California State Board of Pharmacy website was accessed on January 2, 2018, to identify all licensed California pharmacies, excluding pharmacies with canceled, revoked, probationary, or restricted licenses and hospital, correctional, or specialty pharmacies. Thirty trained interviewers posed as potential customers. Using a standardized script, they asked any pharmacy staff: "I heard that you can get naloxone from a pharmacy without a prescription from your doctor. Can I do that at your pharmacy?" If the response was affirmative, they asked what formulations were available, the cash price, and whether naloxone could be billed to insurance. Additional unsolicited information was recorded.
Proportions with 95% confidence intervals, medians with interquartile ranges (IQRs), and χ 2 tests comparing differences in availability by urbanity (census tract designation) and pharmacy type (independent or chain, defined as ≥5 locations) were estimated using Stata version 15.1 (StataCorp). With a power of 85% and α = .05, the sample size required to detect an effect size of 0.1 in χ 2 tests comparing differences in availability by urbanity and pharmacy type was n = 898. Statistical significance was set at a 2-tailed P < .05.
Results | Of 6962 California pharmacies, 6047 were eligible, 1209 were surveyed, and data were collected from 1147 (93.3%). Most pharmacies were urban (98.7%) and part of a chain (66.2%) ( Table 1) . Pharmacist-furnished naloxone was available at 23.5% (95% CI, 21.0%-26.0%) of pharmacies. Differences by urbanity were not statistically significant, although rural pharmacies were underrepresented. There was a significant difference by pharmacy type, with 31.6% (95% CI, 28.3%-35.1%) of chain pharmacies compared with 7.5% (95% CI, 5.1%-10.6%) of independent pharmacies furnishing naloxone (P < .001). Among pharmacies furnishing naloxone (n = 269), 225 (83.6%) offered a nasal formulation ( Table 2) . Fourteen (5.2%) offered combination buprenorphine-naloxone tablets used for treatment of opioid use disorder, not opioid overdose. Of pharmacies furnishing naloxone, 50.6% had nasal naloxone in stock. Chain pharmacies were significantly more likely to have nasal naloxone in stock (52.3%; 95% CI, 46.3%-59.4%) compared with independents (31.0%; 95% CI, 15.3%-50.8%) (P = .03). Regarding insurance billing, a There were 1209 sampled pharmacies available for inclusion. Data were not collected from 62 sampled pharmacies for the following reasons: closed door (n = 33), permanently closed (n = 6), specialty pharmacy (n = 5), medical supply (n = 5), no contact after 3 attempts (n = 4), part of closed health center (n = 3), no working telephone number (n = 2), pet pharmacy (n = 2), mail order (n = 1), and telepharmacy (n = 1). 59.9% of pharmacies replied correctly that pharmacistfurnished naloxone could be billed, with no significant difference by pharmacy type. The median cash price of nasal naloxone (pack of 2) at chain pharmacies was $136 (IQR, $120-$143.50) compared with $150 (IQR, $138.50-$170) (P = .04) at independents. A number of erroneous statements were made by respondents, including that naloxone was a controlled substance, that a tablet formulation was available, and that injectable formulations not appropriate for layperson use were available.
Discussion | Two years after implementation, only 23.5% of a representative sample of California retail pharmacies were furnishing naloxone to patients without a physician prescription. Reasons the practice was not being implemented may include lack of knowledge of legislation, lack of required training, stigma about substance use disorder, and time. 4, 5 With only 50.6% of pharmacies stocking nasal naloxone, patients may face a delay in access to the drug. Limitations include low rural pharmacy representation, inclusion of nonpharmacist respondents, absence of data on reasons why pharmacies were not furnishing naloxone, and restriction to California, although most states have some form of pharmacy-based naloxone distribution. Over the last 2 years, the Board of Pharmacy has provided naloxone training to more than 700 of California's 40 000 pharmacists. Whether naloxone will become more available with training of additional pharmacists and implementation of standardized policies by pharmacy chains needs to be studied.
Naloxone Accessibility Without a Prescriber Encounter Under Standing Orders at Community Pharmacy Chains in Texas
In response to the opioid overdose epidemic, each US state has passed legislation to expand access to naloxone, the opioid overdose antidote. 1 Although naloxone access laws 
